SSTR-TARGETED CONJUGATES AND FORMULATIONS THEREOF
Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, have been designed. Methods of administering the conjugates to a subject in need thereof are provided, for example, to treat or prevent cancer.
1 . A method of treating a tumor of a patient, comprising contacting said patient with a pharmaceutical composition comprising Conjugate 57 and at least one excipient.
2 . The method of claim 1 , wherein the pharmaceutical composition comprising Conjugate 57 is administered intravenously once every 3 weeks.
3 . The method of claim 2 , wherein the patient is treated with the pharmaceutical composition comprising Conjugate 57 for at least 9 weeks.
4 . The method of claim 1 , wherein the pharmaceutical composition comprises mannitol, polyoxyl 15 hydroxystearate and aqueous acetate buffer.
5 . The method of claim 1 , wherein Conjugate 57 has a half-life of about 1.0-2.5 hours.
6 . The method of claim 5 , wherein Conjugate 57 has a half-life of about 1.5 hours, 1.6 hours, 1.7 hours, 1.8 hours, 1.9 hours, or 2.0 hours.
7 . The method of claim 1 , wherein the dosing of Conjugate 57 is 1.0 mg, 2.0 mg, 4.0 mg, 8.0 mg, 12.0 mg, or 18.0 mg.
8 . The method of claim 1 , wherein the chromogranin A (CgA) levels of the patient is reduced.
9 . The method of claim 1 , wherein the neuron specific enolase (NSE) levels of the patient is reduced.
10 . The method of claim 1 , wherein the circulating tumor cell (CTC) levels of the patient is reduced.
11 . The method of claim 1 , wherein the tumor of the patient is a SSTR2 expressing tumor.
12 . The method of claim 11 , wherein the tumor of the patient is gastrointestinal neuroendocrine tumor (GI NET), pancreatic neuroendocrine tumor (PNET), lung neuroendocrine tumor (lung NET), lung large get cell neuroendocrine carcinoma, Pheochromocytoma (Pheo), or small cell lung cancer (SCLC).